GO:0000166 nucleotide binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000166 nucleotide binding describes the molecular function of binding to any nucleotide, a nucleoside esterified with phosphate or oligophosphate at any hydroxyl group on the ribose or deoxyribose.
• Nucleotide binding is central to energy transfer, signal transduction, nucleic acid metabolism, and enzyme catalysis, and is mediated by conserved structural motifs such as Walker A and Walker B.
• Key protein families that bind nucleotides include ABC transporters, septins, histidine triad (HIT) proteins, and many kinases and GTPases.
• Dysregulation of nucleotide binding contributes to cancer, neurodegenerative disorders, and metabolic diseases, making these proteins important therapeutic targets.
• Experimental methods to study nucleotide binding include transient kinetic assays, nucleotide-linked resins, and nucleotide-decorated gold nanoparticles.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal interrogation of nucleotide-binding proteins in disease and development.
Description
Nucleotide binding is a fundamental molecular function that underpins countless biological processes, from energy metabolism to signal transduction and nucleic acid synthesis. The Gene Ontology term GO:0000166, nucleotide binding, is defined as binding to a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose. This broad definition encompasses the binding of ATP, GTP, CTP, UTP, and their deoxyribonucleotide counterparts, as well as cyclic nucleotides and nucleotide analogs. Proteins that bind nucleotides are ubiquitous and include enzymes, transporters, receptors, and regulatory factors. Understanding nucleotide binding is essential for researchers because it governs the activity of many druggable targets and is frequently altered in human disease. For example, mutations in the nucleotide-binding domains of ABC transporters can cause cystic fibrosis and multidrug resistance. Similarly, defects in nucleotide binding by septins or HIT proteins have been linked to cancer and neurodegeneration. The specificity and affinity of nucleotide binding are often regulated by conformational changes and post-translational modifications, making this function a dynamic and highly regulated process. This article provides a comprehensive overview of GO:0000166, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods. By integrating authoritative QuickGO data with real PubMed literature, we aim to equip researchers with a publication-ready resource for studying nucleotide-binding proteins and their roles in health and disease.
nucleotide binding At A Glance
| GO ID | GO:0000166 |
|---|---|
| GO term | nucleotide binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose. |
| Major function | Mediates recognition and interaction with nucleotides such as ATP, GTP, and their derivatives, enabling energy transfer, catalysis, and signaling. |
| Example protein families | ABC transporters, septins, histidine triad proteins, kinases, GTPases |
| Related GO terms | nucleotide transmembrane transporter activity, ATP binding, GTP binding |
| Disease relevance | Cancer, neurodegeneration, metabolic disorders, and infectious diseases |
What Is GO:0000166?
In our own words, GO:0000166 nucleotide binding refers to the ability of a protein or other molecule to selectively and non-covalently interact with a nucleotide. A nucleotide is composed of a nitrogenous base, a five-carbon sugar (ribose or deoxyribose), and one or more phosphate groups. The binding can occur at any hydroxyl group of the sugar, and the phosphate moiety may be a single orthophosphate or an oligophosphate chain. This function is distinct from nucleotide hydrolysis or transfer, although binding is often a prerequisite for catalysis. The term is intentionally broad to capture the diverse ways proteins recognize nucleotides, from high-affinity ATP binding in kinases to transient interactions in signaling GTPases.
Why Is nucleotide binding Important in Cell Biology?
Nucleotide binding is a cornerstone of molecular biology because nucleotides serve as universal energy carriers, signaling molecules, and building blocks for nucleic acids. Proteins that bind nucleotides are involved in nearly every cellular process, including DNA replication, transcription, translation, signal transduction, and metabolism. Consequently, understanding the mechanisms, specificity, and regulation of nucleotide binding is critical for deciphering cellular function and for developing therapeutics. Moreover, many nucleotide-binding proteins are validated drug targets, and their dysfunction is implicated in a wide range of diseases, from cancer to neurodegeneration.
• Nucleotide binding enables energy transfer and catalysis in enzymes such as kinases and ATPases.
• It is essential for signal transduction pathways mediated by GTPases and cyclic nucleotide receptors.
• ABC transporters rely on nucleotide binding to drive substrate transport across membranes, impacting drug resistance.
• Septins require nucleotide binding for filament assembly and cell division.
• Histidine triad proteins bind nucleotides and are involved in mRNA decapping and tumor suppression.
• Defects in nucleotide binding are linked to cancer, neurodegeneration, and metabolic diseases.
• Nucleotide-binding motifs are highly conserved and can be targeted by small-molecule inhibitors.
• Advanced methods like nucleotide-decorated nanoparticles facilitate discovery of novel nucleotide-binding proteins.
• CRISPR screens can identify nucleotide-binding proteins essential for cell fitness and disease.
• Understanding nucleotide binding informs drug design and precision medicine.
What Happens During nucleotide binding?
Nucleotide recognition and initial contact
In simple terms: The protein first recognizes and loosely grabs the nucleotide.
Nucleotide binding begins with the specific recognition of the nucleotide by a binding pocket in the protein. This initial contact is driven by electrostatic interactions between the phosphate groups of the nucleotide and positively charged residues, as well as hydrogen bonding and aromatic stacking with the nucleobase. For example, the nucleotide-binding sites of the SUR1 protein involve distinct residues that coordinate ATP and ADP. Similarly, septins from S. cerevisiae exhibit differential binding properties for GTP and ATP, which are mediated by conserved P-loop motifs. The specificity of this initial recognition determines which nucleotide is bound and influences downstream conformational changes.
Conformational change and tight binding
In simple terms: Once the nucleotide is grabbed, the protein changes shape to hold it tightly.
Upon initial contact, the protein undergoes conformational changes that tighten the binding and often bring catalytic residues into position. This induced-fit mechanism is well documented for ABC exporters like MsbA, where nucleotide binding at the cytoplasmic domains triggers dimerization and a cascade of structural rearrangements. Transient kinetic methods have been used to resolve the steps of DNA binding and nucleotide flipping, revealing that conformational changes can occur on millisecond timescales. These changes are critical for converting the energy of nucleotide binding into mechanical work or chemical catalysis.
Nucleotide hydrolysis and energy coupling
In simple terms: The protein may cut the nucleotide to release energy and drive other processes.
Many nucleotide-binding proteins are also enzymes that hydrolyze the nucleotide (e.g., ATPases and GTPases). Hydrolysis is coupled to functional outputs such as substrate transport, protein synthesis, or signal termination. For instance, the ABC exporter MsbA uses ATP binding and hydrolysis to pump lipopolysaccharides across the inner membrane. The energy from hydrolysis is transduced through conserved motifs like the Walker B glutamate, which positions a water molecule for nucleophilic attack. This coupling is essential for the protein's biological function and is often regulated by accessory factors.
Nucleotide exchange and release
In simple terms: After the job is done, the nucleotide is swapped out or released.
Following hydrolysis or signal completion, the bound nucleotide (or its products) must be released to reset the cycle. Nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) regulate this step for GTPases, while ATP-binding cassette transporters often rely on intrinsic dynamics. For example, the septin nucleotide-binding properties include exchange of GDP for GTP, which is required for filament assembly. The rate of release can be modulated by post-translational modifications or interacting proteins, ensuring tight temporal control of cellular processes.
Regulation by damaged nucleotide binding
In simple terms: Cells have quality-control systems to handle proteins that bind damaged nucleotides.
Damaged nucleotides, such as 8-oxo-GTP, can be incorporated into proteins and cause dysfunction. A comprehensive screening system for damaged nucleotide-binding proteins has been developed to identify proteins that preferentially bind oxidized nucleotides. This quality-control mechanism is important for preventing errors in DNA replication and signaling. The study highlights that nucleotide binding is not only about normal nucleotides but also about recognizing and handling damaged ones, which has implications for aging and cancer.
Key Genes Involved in GO:0000166 nucleotide binding
The following table lists representative genes and proteins that exhibit nucleotide binding activity, along with their major roles and research relevance.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCB1 | ATP-binding cassette transporter; efflux pump | Multidrug resistance in cancer; nucleotide binding drives transport |
| CFTR | Chloride channel; ABC transporter | Cystic fibrosis; nucleotide binding regulates channel gating |
| SEPT2 | Septin filament component; GTP binding | Cell division and cytoskeleton; nucleotide binding affects assembly |
| SEPT7 | Septin filament component; GTP binding | Cancer and neurodegeneration; nucleotide-dependent functions |
| HINT1 | Histidine triad nucleotide-binding protein | Tumor suppressor and neurological disorders |
| HINT2 | Histidine triad nucleotide-binding protein | Mitochondrial apoptosis and cancer metabolism |
| MSBA | ABC exporter; ATP binding | Lipid transport and antibiotic resistance |
| SUR1 | ATP-sensitive potassium channel subunit | Diabetes and hyperinsulinism; nucleotide binding regulates channel activity |
| KRAS | Small GTPase; GTP binding | Cancer; nucleotide binding and hydrolysis control signaling |
| GNAI1 | G protein alpha subunit; GTP binding | Signal transduction; nucleotide exchange regulates activity |
| ATP1A1 | Na+/K+-ATPase; ATP binding | Ion transport; nucleotide binding energizes pumping |
| DNAK | Hsp70 chaperone; ATP binding | Protein folding; nucleotide binding drives allosteric cycle |
| GAPDH | Glycolytic enzyme; NAD+ binding | Metabolism; nucleotide binding for catalysis |
| TUBB | Tubulin; GTP binding | Microtubule dynamics; nucleotide binding regulates polymerization |
| ACTB | Actin; ATP binding | Cytoskeleton; nucleotide binding affects filament turnover |
| POLA1 | DNA polymerase; dNTP binding | DNA replication; nucleotide binding for catalysis |
| RNASEL | Ribonuclease L; ATP binding | Antiviral defense; nucleotide binding for activation |
How Is nucleotide binding Regulated?
Nucleotide binding is regulated at multiple levels. Allosteric effectors, such as magnesium ions, can modulate the affinity for nucleotides by neutralizing phosphate charges. Post-translational modifications, including phosphorylation, can alter the conformation of nucleotide-binding pockets and affect binding kinetics. Additionally, nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) tightly control the GTP-bound state of small GTPases. In the context of damaged nucleotides, cellular quality-control pathways can upregulate proteins that bind oxidized nucleotides to prevent incorporation. Furthermore, the availability of nucleotides themselves is regulated by metabolic pathways, linking nucleotide binding to cellular energy status.
nucleotide binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KRAS | Cancer (pancreatic, lung, colorectal) | Point mutation knock-in (G12D) in cell lines |
| CFTR | Cystic fibrosis | Knock-in of F508del mutation in iPSCs |
| HINT1 | Neuromyotonia and axonal neuropathy | Knockout mouse or patient-derived neurons |
| SUR1 | Congenital hyperinsulinism / diabetes | Knockout of ABCC8 in pancreatic beta cells |
| ABCB1 | Multidrug resistance in cancer | Overexpression in cancer cell lines |
Cancer
Dysregulated nucleotide binding is a hallmark of many cancers. Oncogenic GTPases such as KRAS are locked in a GTP-bound state due to mutations that impair hydrolysis, leading to constitutive proliferative signaling. ABC transporters like ABCB1 bind ATP to pump chemotherapeutic drugs out of cells, causing multidrug resistance. Histidine triad nucleotide-binding protein 2 (HINT2) has been implicated in cancer metabolism and apoptosis, with altered expression in hepatocellular carcinoma. Targeting nucleotide-binding pockets with small molecules is a promising therapeutic strategy.
Neurodegeneration
Nucleotide-binding proteins play critical roles in neuronal function and survival. HINT1 mutations cause neuromyotonia and axonal neuropathy, highlighting the importance of nucleotide binding in the nervous system. Septins, which bind GTP, are involved in neurodegenerative processes such as Parkinson's disease, where their filament assembly is disrupted. Additionally, defects in mitochondrial nucleotide binding can lead to energy failure and neuronal death.
Metabolic disorders
Nucleotide binding is central to metabolic regulation. SUR1, an ATP-binding cassette protein, forms ATP-sensitive potassium channels that couple cellular metabolism to insulin secretion; mutations cause congenital hyperinsulinism or diabetes. Similarly, kinases and ATPases that bind ATP are directly involved in glucose and lipid metabolism. Understanding these interactions can inform treatments for metabolic syndrome.
Infectious diseases
Many pathogens rely on nucleotide-binding proteins for survival and virulence. For example, bacterial ABC transporters like MsbA are essential for membrane integrity and are targets for antibiotics. Viral polymerases bind nucleotide triphosphates to replicate their genomes, and inhibiting these interactions is a common antiviral strategy. Thus, nucleotide binding is a key vulnerability in infectious diseases.
From nucleotide binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of nucleotide binding abolish protein function? | CRISPR knockout of the gene in a relevant cell line |
| Does a specific point mutation in the nucleotide-binding pocket alter affinity? | Point mutation knock-in (e.g., Walker A lysine to alanine) |
| Can a disease-associated mutation be corrected? | Knock-in of wild-type sequence or base editing |
| Where is the nucleotide-binding protein localized? | Tagged knock-in with fluorescent protein (e.g., GFP) |
| Does overexpression drive oncogenic transformation? | Overexpression via lentiviral transduction |
| Which nucleotide-binding proteins are essential for cell fitness? | Genome-wide CRISPR library screening |
How to Study the nucleotide binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Stopped-flow kinetics | Real-time nucleotide binding and hydrolysis rates | Mechanistic studies of ATPases and GTPases |
| Nucleotide-linked resins | Affinity pull-down of nucleotide-binding proteins | Discovery of novel nucleotide binders |
| Gold nanoparticle probes | Binding-induced color change or plasmon shift | Detection of nucleotide-binding proteins in lysates |
| Damaged nucleotide screening | Preference for oxidized nucleotides | Quality control and oxidative stress research |
| Isothermal titration calorimetry | Binding affinity (Kd) and stoichiometry | Characterization of nucleotide-protein interactions |
| CRISPR knockout screens | Essentiality of nucleotide-binding genes | Functional genomics and drug target discovery |
| Cryo-EM | High-resolution structures of nucleotide-bound complexes | Understanding conformational changes |
| Molecular dynamics | Simulated binding dynamics and energetics | Predicting mutation effects |
Transient kinetic methods
Transient kinetic methods, such as stopped-flow fluorescence and rapid-quench, allow real-time monitoring of nucleotide binding and flipping. These techniques can resolve individual steps of binding, conformational changes, and hydrolysis on millisecond to second timescales. They are particularly useful for determining rate constants and identifying intermediates in the reaction pathway.
Nucleotide-linked resins and nanoparticles
Nucleotide-linked resins and nucleotide-decorated gold nanoparticles are powerful tools for identifying and characterizing novel nucleotide-binding proteins. These probes can pull down proteins from cell lysates or visualize binding events via colorimetric or plasmonic readouts. They enable high-throughput screening and discovery of proteins with specific nucleotide preferences.
Screening for damaged nucleotide-binding proteins
A comprehensive screening system has been developed to identify proteins that bind damaged nucleotides, such as 8-oxo-GTP. This system uses nucleotide analogs and competitive binding assays to profile the specificity of nucleotide-binding proteins. It is valuable for studying oxidative stress and DNA repair mechanisms.
Structural biology and computational modeling
X-ray crystallography, cryo-EM, and molecular dynamics simulations provide atomic-level insights into nucleotide binding pockets and conformational changes. For example, mechanistic models of SUR1 nucleotide-binding sites have been built using structural data. Computational docking can predict binding affinities and guide mutagenesis.
How CRISPR Can Be Used to Study GO:0000166 nucleotide binding
Knockout
CRISPR knockout (KO) of genes encoding nucleotide-binding proteins is a powerful approach to study loss-of-function phenotypes. For example, KO of ABCB1 in cancer cell lines can reverse multidrug resistance and sensitize cells to chemotherapy. KO of septins in yeast disrupts filament assembly and cell division. KO models are essential for validating the causal role of nucleotide binding in cellular processes.
Point Mutation
Point mutation knock-in allows precise interrogation of specific residues within nucleotide-binding motifs. For instance, mutating the conserved lysine in the Walker A motif to alanine abolishes ATP binding and can reveal its contribution to protein function. Such models are invaluable for dissecting the mechanistic basis of nucleotide binding and for modeling human disease mutations.
Knock-in
Knock-in of wild-type or mutant nucleotide-binding protein sequences can rescue or induce phenotypes. For example, knocking in a disease-associated mutation in CFTR (e.g., F508del) into iPSCs creates a model for cystic fibrosis. Tagged knock-in (e.g., GFP fusion) enables live-cell imaging of protein localization and dynamics.
Overexpression
Overexpression of nucleotide-binding proteins via CRISPR activation (CRISPRa) or lentiviral vectors can mimic oncogenic states. Overexpressing KRAS with a G12V mutation drives transformation in vitro and in vivo. Overexpression studies help identify gain-of-function effects and potential therapeutic vulnerabilities.
How EDITGENE Supports nucleotide binding Research
Researchers studying nucleotide binding-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as drug resistance, metabolic dysregulation, or neurodegeneration. This requires precise genetic models that can knockout, mutate, or overexpress the gene of interest in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such investigations, from single-gene editing to genome-wide screening.
Contact EDITGENE today to design your custom CRISPR model for nucleotide binding research.
Frequently Asked Questions About nucleotide binding
What is nucleotide binding?
Nucleotide binding is a molecular function (GO:0000166) where a protein or molecule binds to a nucleotide, such as ATP or GTP, through non-covalent interactions.
What genes are involved in nucleotide binding?
Genes encoding ABC transporters (ABCB1, CFTR), septins (SEPT2, SEPT7), histidine triad proteins (HINT1, HINT2), and small GTPases (KRAS) are prominent examples.
How does nucleotide binding affect cell function?
It enables energy transfer, signal transduction, substrate transport, and catalysis, influencing processes like cell division, metabolism, and gene expression.
What diseases are linked to nucleotide binding defects?
Cancer, neurodegeneration, cystic fibrosis, diabetes, and infectious diseases can result from mutations in nucleotide-binding proteins.
What methods are used to study nucleotide binding?
Transient kinetics, nucleotide-linked resins, gold nanoparticle probes, and CRISPR screens are commonly used.
Can CRISPR be used to study nucleotide binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise interrogation of nucleotide-binding protein function.
What is the role of ATP binding in ABC transporters?
ATP binding drives conformational changes that power substrate transport across membranes, and mutations can cause multidrug resistance.
How do septins use nucleotide binding?
Septins bind GTP to assemble filaments essential for cell division and cytoskeletal organization.
What are histidine triad nucleotide-binding proteins?
HIT proteins bind nucleotides and are involved in mRNA decapping, tumor suppression, and neurological disorders.
Why is nucleotide binding important for drug discovery?
Many drugs target nucleotide-binding pockets, and understanding binding specificity can guide development of inhibitors for cancer and infections.
Conclusion
Nucleotide binding (GO:0000166) is a ubiquitous and essential molecular function that governs energy metabolism, signal transduction, and nucleic acid transactions. Its dysregulation is implicated in a broad spectrum of human diseases, from cancer to neurodegeneration. Advances in kinetic methods, nucleotide probes, and CRISPR-based models are accelerating our understanding of nucleotide-binding proteins and their therapeutic potential. EDITGENE's comprehensive CRISPR services empower researchers to dissect these mechanisms with precision and speed.
References
- 1. Yao J et al.. 2023. Histidine triad nucleotide-binding protein 2: From basic science to clinical implications.. Biochem Pharmacol 212:115527 PMID: 37004779
- 2. Vedovato N et al.. 2015. The Nucleotide-Binding Sites of SUR1: A Mechanistic Model.. Biophys J 109(12):2452-2460 PMID: 26682803
- 3. Baur JD et al.. 2019. Dissecting the nucleotide binding properties of the septins from S. cerevisiae.. Cytoskeleton (Hoboken) 76(1):45-54 PMID: 30091242
- 4. Tsuchimoto D et al.. 2010. A comprehensive screening system for damaged nucleotide-binding proteins.. Mutat Res 703(1):37-42 PMID: 20542141
- 5. Hendershot JM et al.. 2017. Transient Kinetic Methods for Mechanistic Characterization of DNA Binding and Nucleotide Flipping.. Methods Enzymol 592:377-415 PMID: 28668128
- 6. Chauhan SS et al.. 2023. Generation of nucleotide-linked resins for identification of novel binding proteins.. Methods Enzymol 679:323-330 PMID: 36682867
- 7. Perzanowska O et al.. 2021. Nucleotide-decorated AuNPs as probes for nucleotide-binding proteins.. Sci Rep 11(1):15741 PMID: 34344911
- 8. Kaur H et al.. 2018. Unexplored Nucleotide Binding Modes for the ABC Exporter MsbA.. J Am Chem Soc 140(43):14112-14125 PMID: 30289253
